• Explore /
  • Poster
  • / Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.

Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.

Abstract Poster

Authors

Wungki Park

Wungki Park

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY;

Wungki Park , Eileen Mary O'Reilly , Junji Furuse , Chung-Pin Li , Do-Youn Oh , Rocio Garcia-Carbonero , Gaël Roth , Ho-Jin Lee , Pranob P. Bhattacharya , Diarmuid Martin Moran , Jianning Yang , Futoshi Kunieda

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Other

Clinical Trial Registration Number

NCT03816163

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS782)

DOI

10.1200/JCO.2023.41.4_suppl.TPS782

Abstract #

TPS782

Poster Bd #

Q18

Abstract Disclosures

Similar Posters

First Author: Wungki Park

First Author: Wungki Park

First Author: John Ebben

First Author: Benedikt Westphalen